{"id":55348,"date":"2023-03-30T13:04:18","date_gmt":"2023-03-30T11:04:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/"},"modified":"2023-03-30T13:04:18","modified_gmt":"2023-03-30T11:04:18","slug":"beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/","title":{"rendered":"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity"},"content":{"rendered":"
\n

\nPryor will spearhead BeiGene\u2019s efforts to pair global health equity with diversity and inclusion<\/i>\n<\/p>\n

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BGNE<\/a> #BeiGene<\/a>–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nMr. Pryor has more than 30 years of experience in Diversity, Equity, Inclusion & Belonging (DEI&B) efforts, having successfully built transformational DEI&B programs for biotechnology companies, as well as global consumer-focused businesses. In this newly created role, he will lead BeiGene\u2019s efforts to elevate the company\u2019s health equity and DEI&B initiatives, ensuring representation is at the forefront in BeiGene\u2019s commitment to colleagues as well as patients, caregivers, and other external stakeholders in combatting disparities in healthcare.\n<\/p>\n

\n\u201cAs a global company determined to deliver accessible and affordable medicines to more patients around the world, health equity and diversity are central values for BeiGene,\u201d said Graham Hardiman, Head of Global Human Resources at BeiGene. \u201cJulius brings a wealth of experience to our team and a commitment to advancing corporate diversity initiatives as well as improving the lives of patients and caregivers. We are excited to expand our efforts in this space under Julius\u2019 transformative leadership.\u201d\n<\/p>\n

\nIn addition to Mr. Pryor\u2019s appointment, BeiGene has formed an internal Diversity & Health Equity Council with the goal of expanding the company\u2019s DEI&B initiatives as well as the affordability and accessibility of its medicines and ensuring greater patient diversity in the company\u2019s global clinical trial ecosystem, which has enrolled more than 20,000 patients to date across more than 45 countries and regions.\n<\/p>\n

\n\u201cBeiGene is engaging in a fundamental shift in how it jointly considers the unique needs of the company\u2019s diverse external stakeholder base and its employees. I\u2019m excited to join this team at a pivotal moment in its growth and continue to ensure that equity and diversity are at the center of our work moving forward,\u201d said Pryor.\n<\/p>\n

\nMr. Pryor joins BeiGene from the J. Pryor Group, where he served as a General Managing Partner. Previously, Mr. Pryor held executive roles at Johnson & Johnson (J&J), Genentech, Coca-Cola Enterprises (CCE), Russell Athletic, Abbott, Takeda, and Cerner. He was Vice President of Global Diversity at both J&J and CCE, and served as Head of Innovation, Diversity & Inclusion at Genentech. He is chair of the Board of Directors at the Center for Healthcare Innovation, a nonprofit research and educational institute making healthcare more equitable.\n<\/p>\n

\nAbout BeiGene<\/b>\n<\/p>\n

\nBeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Basel, Beijing and Cambridge, Mass. To learn more about BeiGene, please visit www.beigene.com<\/a> and follow us on Twitter at @BeiGeneGlobal.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of the Global Head of Diversity and Health Equity to lead BeiGene\u2019s health equity and DEI&B initiatives to combat disparities in healthcare, the potential for the Diversity & Heath Equity Council to improve the affordability and accessibility of BeiGene\u2019s medicines and to provide greater patient diversity in BeiGene\u2019s clinical trials, and BeiGene\u2019s plans, commitments, aspirations, and goals under the heading \u201cAbout BeiGene.\u201d Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services; BeiGene\u2019s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and the impact of the COVID-19 pandemic on BeiGene\u2019s clinical development, regulatory, commercial, manufacturing, and other operations, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in BeiGene\u2019s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors
\n
Kevin Mannix
\n
+1 857-302-5189
\n
ir@beigene.com<\/a>\n<\/p>\n

\nMedia
\n
Kyle Blankenship
\n
+1 667-351-5176
\n
media@beigene.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Pryor will spearhead BeiGene\u2019s efforts to pair global health equity with diversity and inclusion BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BGNE #BeiGene–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately. Mr. Pryor … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55348","6":"format-standard","7":"category-industry"},"yoast_head":"\nBeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Pryor will spearhead BeiGene\u2019s efforts to pair global health equity with diversity and inclusion BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BGNE #BeiGene–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately. Mr. Pryor ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-30T11:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230330005198\/en\/1751464\/21\/Julius_Pryor.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity\",\"datePublished\":\"2023-03-30T11:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/\"},\"wordCount\":905,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005198\\\/en\\\/1751464\\\/21\\\/Julius_Pryor.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/\",\"name\":\"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005198\\\/en\\\/1751464\\\/21\\\/Julius_Pryor.jpg\",\"datePublished\":\"2023-03-30T11:04:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005198\\\/en\\\/1751464\\\/21\\\/Julius_Pryor.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005198\\\/en\\\/1751464\\\/21\\\/Julius_Pryor.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/","og_locale":"en_US","og_type":"article","og_title":"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity - Pharma Trend","og_description":"Pryor will spearhead BeiGene\u2019s efforts to pair global health equity with diversity and inclusion BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BGNE #BeiGene–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately. Mr. Pryor ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-30T11:04:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230330005198\/en\/1751464\/21\/Julius_Pryor.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity","datePublished":"2023-03-30T11:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/"},"wordCount":905,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005198\/en\/1751464\/21\/Julius_Pryor.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/","url":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/","name":"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005198\/en\/1751464\/21\/Julius_Pryor.jpg","datePublished":"2023-03-30T11:04:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230330005198\/en\/1751464\/21\/Julius_Pryor.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230330005198\/en\/1751464\/21\/Julius_Pryor.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-julius-pryor-iii-as-first-global-head-of-diversity-and-health-equity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55348"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55348\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}